Trial Search Results
TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)
Based on both pre-clinical and clinical data, it may be advantageous to administer a cancer vaccine before chemotherapy to enhance immune responses, thus leading to a more effective therapeutic approach for subjects with metastatic HRPC. This clinical study will evaluate the role of combination therapy of TroVax® plus Docetaxel vs. Docetaxel alone on the progression free survival (PFS) of subjects with HRPC.
Stanford is currently not accepting patients for this trial.
- Drug: Docetaxel
- Drug: TroVax + Docetaxel
1. Signed & dated written informed consent obtained from subject in accordance w/local
2. Histologically confirmed conventional and/or mucinous adenocarcinoma of the prostate.
If histological confirmation is not available, cytological confirmation will be
permitted in lieu.
3. Must meet one of following 3 criteria for progressive disease following androgen
A. Subjects w/nodal or visceral metastases:
Must have progressive disease defined by RECIST criteria or defined by the Prostate Cancer
Clinical Trials Working Group II (Scher et al. 2008).
B. Subjects w/no measurable disease:
PSA only disease must have an elevated PSA as defined by Consensus Criteria Prostate Cancer
Clinical Trials Working Group II (Scher et al. 2008). PSA must indicate progressive disease
defined as rising PSA values, at least 7 days apart, >2 ng/mL in the 28 days prior to
C. Subjects w/bone involvement:
New disease on bone scan as defined by Consensus Criteria Prostate Cancer Clinical Trials
Working Group II (Scher et al. 2008). 4. Subjects on stable dose of bisphosphonates showing
subsequent tumor progression may continue on this medication; however, subjects are not
allowed to initiate bisphosphonate therapy w/in 28 days prior to starting study treatment
at Week 1 or at any time after that during the study, 5. Must be clinically
immunocompetent. Clinical immunocompetence assumed unless subject has been diagnosed as
immunosuppressed, is receiving immunosuppressive chemotherapy for oncology disorders, or is
receiving immunosuppressive therapy following transplant, in which case they will be
6. Subject free of clinically apparent/active autoimmune disease (no prior confirmed
diagnosis or treatment for autoimmune disease including Systemic Lupus Erythematosis,
Grave's Disease, Hashimoto's Thyroiditis, Multiple Sclerosis, & Rheumatoid Arthritis).
7. Subject has adequate bone marrow function defined by Absolute Lymphocyte Count (ALC) ≥
500/µL, Absolute Neutrophil Count (ANC) >1200/µL, Platelet Count >100,000/µL.
8. Subject has peripheral neuropathy grade ≤1. 9. Subject has ECOG status of 0 or 1. 10.
Minimum life expectancy ≥6 months. 11. Progressive disease (as defined above) must be
documented after discontinuation of the hormonal and anti-androgen therapy.
12. Subject continues to stay on medical treatment such as LHRH agonists or LHRH
antagonists to maintain testosterone value of <50ng/dL.
1. Subject has received prior chemotherapy for prostate cancer at any time. Subject has
received chemotherapy for any other reason within five years of screening.
2. Subject is receiving any other hormonal therapy, including any dose of Megestrol
Acetate, Finasteride, any herbal product known to decrease PSA levels (e.g., Saw
Palmetto & PC-SPES), or any systemic corticosteroid must discontinue agent for at
least 4 weeks prior to the anticipated Week 1 visit. LHRH agonists or LHRH antagonists
do not need to be discontinued.
3. Subject has started bisphosphonate or denosumab therapy less than 28 days before the
anticipated Week 1 visit.
4. Subject is using supplements or complementary medicines/botanicals. Subjects should
review label w/their doctor prior to enrolment. Exceptions to this exclusion:
- Conventional multivitamin supplements
- Soy supplements
- Vitamin E
- Fish oil supplements
- Vitamin D
- Glucosamine supplements
- Age-related eye disease vitamins
- Ginkgo biloba
5. Subject has had major surgery or radiation therapy completed <4 weeks prior to
6. Corticosteroids are not permitted except for (a) nasal sprays and inhalers, (b) orally
prescribed as replacement therapy in the case of adrenal insufficiency, (c) oral or IV
dexamethasone administration used acutely in combination with docetaxel, (d)
parenteral use on a single occasion, (e) low dose parenteral use for a maximum of 5
days and (f) acute and sporadic parenteral use for acute asthma.
7. Subject is known to test positive for HIV or hepatitis B or C.
8. Subject receiving concurrent chemotherapy, immunotherapy, radiotherapy or
9. Subject has Platelet count >400,000/μL; Monocytes >80,000/μL; Haemoglobin <11g/dL.
10. Subject has cerebral metastases (known from previous investigations or clinically
11. Subject has serum testosterone >50ng/dL.
12. Subject has rheumatoid disease (asymptomatic subjects w/controlled & rarely flaring
rheumatoid arthritis are also excluded).
13. Subject exhibits evidence of symptomatic congestive heart failure, pulmonary embolus,
vascular thrombosis, transient ischemic attack, cerebrovascular accident, unstable
angina, myocardial infarction or active ischemia on ECG. If an ECG taken prior to
screening but within 28 days of the anticipated Week 1 visit is not available, an ECG
must be performed at screening.
14. Subject has uncontrolled severe hypertension >150/100mm Hg (if controlled w/medication
this is not an exclusion).
15. Subject is hypotensive.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study